Cannabis Bioscience International Holdings, Inc.
Cannabis Bioscience International Holdings, Inc. is a Colorado-based company that has repositioned itself around medical cannabis education, clinical research services, and cannabidiol product development. It operates through three main businesses: Pharmacology University for cannabis-related education and consulting, Alpha Research Institute for clinical trials and research services, and a planned CBD product line under the VitaCookies name. The company also describes an intellectual property portfolio that includes patent applications, trademarks, and medical formulations tied to cannabis and biotechnology applications. Its business model is early-stage and capital constrained, with management explicitly stating that continued operations depend on raising funding and growing revenue from these activities.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueCourses, seminars, certification programs, and training content for physicians, industry workers, and the public.
Sponsor and CRO services for clinical trials, including studies that may involve cannabis and CBD products.
Planned manufacture, marketing, and sale of cannabidiol-based consumer products under VitaCookies.
Digital publishing, marketing support, consulting, and franchise-related activities tied to medical cannabis education.
Products
Reported · share of revenue- Clinical Trials99.6 %
- Merchandise0.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells primarily to participants in the medical cannabis ecosystem rather than to a broad consumer base. Its education business targets physicians, industry workers, and general learners who need cannabis training, certification, and regulatory context. Its research business serves sponsors and third parties that need clinical trial execution or research support in therapeutic areas, including studies involving cannabis and CBD products. The CBD business is intended to reach end consumers through VitaCookies products, while the company’s IP and educational materials support both commercial and institutional users seeking cannabis-related knowledge and product development capabilities.
Buy certification courses and seminars focused on medical cannabis, clinical use, and related legal/ethical issues.
Purchase training and certification to support operational knowledge, compliance, and professional development.
Engage Alpha Research Institute for clinical trial services and research execution in therapeutic areas.
Buy educational materials and seminars covering cannabis history, medicinal value, and industry basics.
Potential buyers of VitaCookies cannabidiol products once commercialized.
Strategy
Management’s strategy is to build a niche position in medical cannabis science by combining education, clinical research, and product development under one umbrella. The company emphasizes intellectual property creation, including patent applications, trademarks, and medical formulations, as a way to differentiate itself despite limited capital and manpower. It also expects future growth from regulatory change, including broader acceptance of medical cannabis research and eventual commercialization of VitaCookies CBD products. Near term, the company’s survival strategy is to raise capital, expand sales of existing services, and convert its educational and research platform into recurring revenue.
The company believes product sales could create a new revenue stream and help move it toward profitability.
Education is a core operating business and can be scaled through online delivery and seminars.
Clinical trials provide service revenue and reinforce the company’s scientific positioning.
Patents, trademarks, and policy participation may support differentiation and market legitimacy.
Geography
The company is headquartered in the United States and repeatedly describes its education business as serving the U.S. market, with additional activity in Latin America and worldwide through online education. Its clinical research and CBD initiatives are also framed around U.S. cannabis and hemp regulatory developments, which are central to demand and commercialization. Because the business is still small and early-stage, geography matters less through physical manufacturing footprint and more through where cannabis laws, research permissions, and online demand allow the company to sell. The company’s exposure is therefore concentrated in the United States, with incremental reach into Latin America and other markets via digital delivery.
Risks
The company is highly exposed to going-concern and financing risk because management states it needs substantial additional capital to fund operations and repay debts. Its revenue base is small and uneven, with quarterly results showing that clinical trial contract volume can drop materially from period to period, which makes earnings volatile and hard to forecast. The business also depends on cannabis and hemp regulation, so changes in federal or state policy, DEA actions, or clinical research rules can either enable or restrict demand for its services and products. As a micro-cap company with limited capital and manpower, it faces execution risk in launching VitaCookies, scaling education, and converting IP into commercial value. More generally, the cannabis industry carries legal, compliance, reputational, and commercialization risks because market access remains fragmented and product acceptance is still evolving.
Management disclosed substantial doubt about the ability to continue as a going concern and said the company needs additional capital to fund operations and repay debts.
Exposure: Entire business
Education, research, and CBD commercialization all depend on legal access to cannabis/hemp and on the pace of federal regulatory change.
Exposure: U.S. cannabis research and CBD commercialization
Clinical trial revenue can change sharply based on the number and timing of contracts in a quarter.
Exposure: Alpha Research Institute
Management indicated future funding may come from private sales of common stock or convertible securities at discounts.
Exposure: Shareholders
Accounting
Judgemental itemsThe company has multiple revenue streams with different service delivery patterns, so timing of recognition affects quarterly results.
Impact: Clinical trial contracts and education sales
Officer and director compensation in stock reduces cash usage but increases operating expense under GAAP.
Impact: Operating loss and net loss
Amortization of discounts and fair value changes can create non-operating volatility in reported earnings.
Impact: Net loss and comparability across periods
Liquidity stress increases the importance of management estimates for receivables, accrued expenses, and deferred tax asset valuation.
Impact: Balance sheet and earnings quality
Similar listed companies
Publicly listed companies with a comparable business focus.
BioScience Health Innovations, Inc.
BHIC · Services-Computer Processing & Data Preparation
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Cannapharmarx, Inc.
CPMD · Pharmaceutical Preparations
CV Sciences, Inc.
CVSI · Pharmaceutical Preparations
Charlie's Holdings, Inc.
CHUC · Medicinal Chemicals & Botanical Products
Bespoke Extracts, Inc.
BSPK · Pharmaceutical Preparations
Last updated: 24/09/2026